HFNO (High-Flow Nasal Oxygen) implementation study in pediatric wards: documentation, feasibility, acceptability
Study design
Mixed method study
Context
Respiratory distress is one of the most common life-threatening presentations in neonates and children. The mainstay of treatment entails supportive therapies, notably supplemental oxygen delivery. Breathing cool, dry gases can result in mucosal damage, reduced ciliary motility, and bronchospasm. Humidified high-flow nasal cannula (HHFNC) is used to deliver a continuous flow of warmed and humidified air to improve ventilation and oxygenation in moderate-to-severe respiratory distress.
In 2020, before the use of High-Flow Nasal Oxygen (HFNO) in COVID-19 adult care, MSF implemented its use in neonatology and pediatrics at Al-Salaam Hospital in the city of Khameer, North Yemen (3 devices).
The study findings should help MSF in the decision of further deployment of HFNO in other projects where the HFNO is likely to be useful.
Our role
Coordination
Partners
- Ministries of Health in the countries where the study is being conducted
Objective
- Describe the implementation of HFNO in pediatric units from the user perspectives and from the child’s mother perspectives.
- Describe the infants benefiting from HFNO, including their outcome.
Specific objectives
- Describe the different aspects of the implementation: training, daily use of the machine, maintenance, consumables.
- Perception and acceptability by the health care staff (clinicians, nurses, biomed, managers), the mother / caretaker
- Provide the cost of the different steps of implementation
